In contrast to the in vitro data, in prospective clinical studies a 12 month treatment with a GnRH agonist and a 12 week treatment with a GnRH agonist concomitant with bicalutamide, respectively, showed no increased levels of the inflammatory markers C-reactive protein and resistin in peripheral blood of prostate cancer patients [36, 42]. This evidence concerns the gene GNRH1 and prostate cancer.